Lite Strategy, Inc. Reports Unregistered Equity Sales
Ticker: LITS · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Lite Strategy, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00000002, $3.4199 |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-securities, equity-sale, capital-raise
TL;DR
Lite Strategy (fka MEI Pharma) sold unregistered equity, watch for dilution.
AI Summary
Lite Strategy, Inc. (formerly MEI Pharma, Inc.) filed an 8-K on September 15, 2025, reporting unregistered sales of equity securities on September 10, 2025. The company, incorporated in Delaware, is in the Pharmaceutical Preparations sector and is headquartered in San Diego, California.
Why It Matters
This filing indicates potential dilution for existing shareholders as new equity was issued without a prior public offering. Investors should monitor future filings for details on the terms of these sales.
Risk Assessment
Risk Level: medium — Unregistered sales can lead to dilution and signal potential financial distress or a need for capital, requiring further investigation.
Key Players & Entities
- Lite Strategy, Inc. (company) — Registrant
- MEI Pharma, Inc. (company) — Former Name
- September 10, 2025 (date) — Date of earliest event reported
- September 15, 2025 (date) — Date of Report
- San Diego, California (location) — Principal Executive Offices
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities in the provided text.
Were these sales to specific investors or a group?
The filing mentions 'Unregistered Sales of Equity Securities' but does not detail the recipients of these securities in the provided text.
What was the purpose of these unregistered sales?
The filing does not disclose the specific purpose for the unregistered sales of equity securities in the provided text.
What is the company's primary business activity?
Lite Strategy, Inc. is in the Pharmaceutical Preparations sector, SIC code 2834.
When did the company change its name from MEI Pharma, Inc.?
The filing indicates the former name was MEI Pharma, Inc., but the date of the name change is not explicitly stated in the provided text snippet.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-09-15 16:00:26
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value LITS The Nasdaq Stock Mar
- $3.4199 — Common Stock"), at an offering price of $3.4199 per Pre-Funded Warrant. The Pre-Funded
Filing Documents
- lits-20250910.htm (8-K) — 42KB
- 0001193125-25-203520.txt ( ) — 148KB
- lits-20250910.xsd (EX-101.SCH) — 25KB
- lits-20250910_htm.xml (XML) — 5KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, Lite Strategy, Inc. (the "Company") issued pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 6,022,869 shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), at an offering price of $3.4199 per Pre-Funded Warrant. The Pre-Funded Warrants were immediately exercisable, and were issued to one of the investors under the securities purchase agreements entered into on July 17, 2025 by the Company and the various purchasers thereunder in a private placement offering (the "PIPE Offering"). On September 10, 2025, the above-referenced investor exercised 1,595,000 Pre-Funded Warrants in a cashless exercise to purchase 1,594,944 shares of Common Stock. The Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder for transactions by an issuer not involving a public offering to issue the Pre-Funded Warrant and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrant. The description of the Pre-Funded Warrant is qualified in its entirety by the full text of the form of Pre-Funded Warrant which is filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed on July 22, 2025, and incorporated by reference herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lite Strategy, Inc. Date: September 15, 2025 By: /a/ Justin J. File Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary